Drugs / 18F-metaFluorobenzylguanidine
18F-metaFluorobenzylguanidine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06965621 Comparator | Nov 2025 → Oct 2026 expected | cardiomyopathy, heart failure | Innervate Radiopharmaceuticals LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-metaFluorobenzylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06965621 ↗ |
| Modality | Diagnostic / imaging agent | “PET Radiopharmaceutical to assess myocardial sympathetic innervation” NCT06965621 ↗ |
| Route | Intravenous | “administered intravenously” NCT06965621 ↗ |